Furthermore, treatment with anti-IL-27 blocking antibodies could protect against secondary pneumococcal infection, indicating that immunomodulatory therapy aimed at antagonizing IL-27 may provide a potential therapeutic intervention for humans susceptible to postinfluenza pneumococcal pneumonia. The gene discussed is IL27; the disease is pneumococcal infection.